Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
GCN5 CRISPR Activation Plasmid (h): sc-400767-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GCN5 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- GCN5 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by GCN5 CRISPR Activation Plasmid (h) and GCN5 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the KAT2A transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: GCN5 Antibody (A-11): sc-365321
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GCN5 CRISPR Activation Plasmid (h) | sc-400767-ACT | 20 µg | $397.00 | |||
GCN5 CRISPR Activation Plasmid (h2) | sc-400767-ACT-2 | 20 µg | $397.00 |
Human KAT2A encodes GCN5, a lysine acetyltransferase that catalyzes histone H3 acetylation (including H3K9 and H3K14) to promote open chromatin and transcriptional competence. GCN5 functions within multi-subunit coactivator complexes such as SAGA and ATAC, coupling histone acetylation with transcription initiation and elongation programs that regulate cell cycle progression, DNA damage responses, and lineage-specific gene expression. Through acetylation of histone and non-histone substrates, KAT2A integrates signaling inputs into chromatin-based control of proliferation and differentiation. Altered KAT2A/GCN5 activity and associated epigenetic dysregulation are implicated in oncogenic transcriptional networks and other diseases linked to aberrant chromatin remodeling.
GCN5 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous KAT2A expression without altering the underlying DNA sequence.
GCN5 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the KAT2A locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the KAT2A transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous GCN5 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native KAT2A locus and enabling the study of GCN5-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of GCN5 pathway restoration in tumor cells with silenced or reduced KAT2A expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.